New drug approved on NHS for multiple sclerosisPublished: 21 February 2022 Ponvory (ponesimod) has been approved for use on the NHS in England and Wales by the National Institute for Health and Care Excellence (NICE) for active relapsing remitting multiple sclerosis (MS). This decision reverses NICE’s earlier rejection of Ponvory which came last October. Ponvory is taken once daily as a tablet and was demonstrated to reduce relapse rate by 30% when compared with Aubagio (teriflunimide) and reduced active lesions seen by MRI. The treatment was approved in Scotland in November for use on the NHS. In England the NHS has to support prescribing of the drug within three months, and in Wales, two months. Other Stories You May Be Interested In... News Study finds MS may marginally increase cervical cancer risk View article News Antibodies detected in blood of 10% of MS patients years before diagnosis View article News Stroke risk higher in people with MS, study finds View article